BACKGROUND: Limited information exists about effects of different highly active antiretroviral therapy (HAART) regimens and duration of regimens on mother-to-child transmission (MTCT) of HIV among women in Africa who start treatment for advanced immunosuppression. METHODS: Between January 2004 to August 2008, 1142 women were followed at antenatal antiretroviral clinics in Johannesburg. Predictors of MTCT (positive infant HIV DNA polymerase chain reaction at 4-6 weeks) were assessed with multivariate logistic regression. RESULTS: Mean age was 30.2 years (SD = 5.0) and median baseline CD4 count was 161 cells per cubic millimeter (SD = 84.3). HAART duration at time of delivery was a mean 10.7 weeks (SD = 7.4) for the 85% of women who initiated treatment during pregnancy and 93.4 weeks (SD = 37.7) for those who became pregnant on HAART. Overall MTCT rate was 4.9% (43 of 874), with no differences detected between HAART regimens. MTCT rates were lower in women who became pregnant on HAART than those initiating HAART during pregnancy (0.7% versus 5.7%; P = 0.01). In the latter group, each additional week of treatment reduced odds of transmission by 8% (95% confidence interval: 0.87 to 0.99, P = 0.02). CONCLUSIONS: Late initiation of HAART is associated with increased risk of MTCT. Strategies are needed to facilitate earlier identification of HIV-infected women.
BACKGROUND: Limited information exists about effects of different highly active antiretroviral therapy (HAART) regimens and duration of regimens on mother-to-child transmission (MTCT) of HIV among women in Africa who start treatment for advanced immunosuppression. METHODS: Between January 2004 to August 2008, 1142 women were followed at antenatal antiretroviral clinics in Johannesburg. Predictors of MTCT (positive infantHIV DNA polymerase chain reaction at 4-6 weeks) were assessed with multivariate logistic regression. RESULTS: Mean age was 30.2 years (SD = 5.0) and median baseline CD4 count was 161 cells per cubic millimeter (SD = 84.3). HAART duration at time of delivery was a mean 10.7 weeks (SD = 7.4) for the 85% of women who initiated treatment during pregnancy and 93.4 weeks (SD = 37.7) for those who became pregnant on HAART. Overall MTCT rate was 4.9% (43 of 874), with no differences detected between HAART regimens. MTCT rates were lower in women who became pregnant on HAART than those initiating HAART during pregnancy (0.7% versus 5.7%; P = 0.01). In the latter group, each additional week of treatment reduced odds of transmission by 8% (95% confidence interval: 0.87 to 0.99, P = 0.02). CONCLUSIONS: Late initiation of HAART is associated with increased risk of MTCT. Strategies are needed to facilitate earlier identification of HIV-infectedwomen.
Authors: Jeannine F J B Nellen; Igor Schillevoort; Ferdinand W N M Wit; Alina S Bergshoeff; Mieke H Godfried; Kees Boer; Joep M A Lange; David M Burger; Jan M Prins Journal: Clin Infect Dis Date: 2004-08-16 Impact factor: 9.079
Authors: Alejandro Dorenbaum; Coleen K Cunningham; Richard D Gelber; Mary Culnane; Lynne Mofenson; Paula Britto; Claire Rekacewicz; Marie-Louise Newell; Jean Francois Delfraissy; Bethann Cunningham-Schrader; Mark Mirochnick; John L Sullivan Journal: JAMA Date: 2002-07-10 Impact factor: 56.272
Authors: D N Burns; S Landesman; L R Muenz; R P Nugent; J J Goedert; H Minkoff; J H Walsh; H Mendez; A Rubinstein; A Willoughby Journal: J Acquir Immune Defic Syndr (1988) Date: 1994-07
Authors: Sharon Walmsley; Barry Bernstein; Martin King; José Arribas; Gildon Beall; Peter Ruane; Margaret Johnson; David Johnson; Richard Lalonde; Anthony Japour; Scott Brun; Eugene Sun Journal: N Engl J Med Date: 2002-06-27 Impact factor: 91.245
Authors: Carla J Chibwesha; Mark J Giganti; Nande Putta; Namwinga Chintu; Jessica Mulindwa; Benjamin J Dorton; Benjamin H Chi; Jeffrey S A Stringer; Elizabeth M Stringer Journal: J Acquir Immune Defic Syndr Date: 2011-10-01 Impact factor: 3.731
Authors: Leigh F Johnson; Kathryn Stinson; Marie-Louise Newell; Ruth M Bland; Harry Moultrie; Mary-Ann Davies; Thomas M Rehle; Rob E Dorrington; Gayle G Sherman Journal: J Acquir Immune Defic Syndr Date: 2012-04-01 Impact factor: 3.731
Authors: Kate Clouse; Constance Mongwenyana; Melda Musina; Dorah Bokaba; Lawrence Long; Mhairi Maskew; Aima Ahonkhai; Matthew P Fox Journal: AIDS Care Date: 2017-10-25
Authors: A E Ezeamama; C Duggan; K P Manji; D Spiegelman; E Hertzmark; R J Bosch; R Kupka; J O Okuma; R Kisenge; S Aboud; W W Fawzi Journal: HIV Med Date: 2013-11-11 Impact factor: 3.180
Authors: Kate Clouse; Audrey Pettifor; Kate Shearer; Mhairi Maskew; Jean Bassett; Bruce Larson; Annelies Van Rie; Ian Sanne; Matthew P Fox Journal: Trop Med Int Health Date: 2013-02-03 Impact factor: 2.622